GSK

Elan enters $1 billion royalty deal with Theravance over potential respiratory drug sales

Elan enters $1 billion royalty deal with Theravance over potential respiratory drug sales

Yahoo/AP

A Closer Look at GlaxoSmithKline's Dividend Potential

A Closer Look at GlaxoSmithKline's Dividend Potential

Motley Fool

This Week in Biotech

This Week in Biotech

Motley Fool

Breo Ellipta gains US approval for the treatment of COPD

Breo Ellipta gains US approval for the treatment of COPD

Yahoo/PR Newswire

Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived

Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived

Seeking Alpha

Merck, Glaxo Reduce HPV Vaccine Prices in Poorest Regions

Merck, Glaxo Reduce HPV Vaccine Prices in Poorest Regions

Bloomberg

The pharma spin-offs have just begun, bankers figure

The pharma spin-offs have just begun, bankers figure

Fierce Pharma

Antibiotics May Relieve Chronic Lower Back Pain Cases

Antibiotics May Relieve Chronic Lower Back Pain Cases

Bloomberg

REUTERS SUMMIT-Drug industry CEOs plotting more carve-outs

REUTERS SUMMIT-Drug industry CEOs plotting more carve-outs

Reuters

Netupitant Results Could Roil Tesaro In May

Netupitant Results Could Roil Tesaro In May

Seeking Alpha